16 – 30 of 46
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2008
-
Mark
Establishment and implementation of common guidelines for 3D treatment planning for breast cancer in southern and western Sweden
(
- Contribution to journal › Published meeting abstract
-
Mark
SORENESS AND SENSITIVITY TO SUN EXPOSURE 10 TO 16 YEARS AFTER BREAST CANCER RADIOTHERAPY
(
- Contribution to journal › Published meeting abstract
- 2006
-
Mark
Time dependent effects of tamoxifen treatment on cardiovascular morbidity
(
- Contribution to journal › Published meeting abstract
- 2005
-
Mark
The cost-effectiveness of post-operative radiotherapy after breast conservation surgery in stage I-II breast cancer in Sweden
(
- Contribution to journal › Published meeting abstract
- 2003
-
Mark
Prolonged tamoxifen therapy; effects on contralateral breast cancer, endometrial cancer incidence and cardiovascular mortality
(
- Contribution to journal › Published meeting abstract
- 2001
-
Mark
DNA-synthesizing enzymes in breast cancer (thymidine kinase, thymidylate synthase and thymidylate kinase) : association with flow cytometric S-phase fraction and relative prognostic importance in node-negative premenopausal patients
(
- Contribution to journal › Article
-
Mark
Image cytometric Auer class-I identifies a real low risk group among lymph node negative premenopausal breast cancer patients
(
- Contribution to journal › Published meeting abstract
-
Mark
Timing of quality of life (QoL) assessments as a source of error in oncological trials
(
- Contribution to journal › Article
- 2000
-
Mark
ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer
2000) In Annals of oncology : official journal of the European Society for Medical Oncology 11(12). p.1545-1550(
- Contribution to journal › Article
-
Mark
A randomised study of sector resection with and without radiotherapy for women with node-negative stage I and II breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group
(
- Contribution to journal › Article
- 1999
-
Mark
Predictive value of P53, MDM-2, P21-expression, KI-67 for response to docetaxel or methotrexate-fluorouracil (MF) in advanced breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
Predictive value c-erB-B2 expression for response to docetaxel (D) or methotrexate-fluorouracil (MF) in advanced breast cancer
(
- Contribution to journal › Published meeting abstract
- 1998
-
Mark
Urokinase plasminogen activator and flow cytometric S-phase fraction as prognostic indicators in breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
A dose intensity study of epirubicin weekly for disseminated breast cancer
(
- Contribution to journal › Published meeting abstract